Severe Cutaneous Adverse Reactions Associated with Immune Checkpoint Inhibitors: A Systematic Review of Clinical Characteristics and Management

Abstract

Keywords

severe cutaneous adverse reaction Stevens-Johnson syndrome toxic epidermal necrolysis drug reaction with eosinophilia and systemic symptoms acute generalized exanthematous pustulosis immune checkpoint inhibitor systematic review

Get full access to this article

View all access options for this article.

References

Ingen-Housz-Oro

Milpied

Bensaid

, et al. Drug reactions with eosinophilia and systemic symptoms induced by immune checkpoint inhibitors: an international cohort of 13 cases. Melanoma Res. 2023;33(2):155-158. doi:10.1097/CMR.0000000000000877

Saw

Lee

. Pembrolizumab-induced Stevens-Johnson syndrome in non-melanoma patients. Eur J Cancer. 2017;81:237-239. doi:10.1016/j.ejca.2017.03.026

Ziemer

Miedema

Smith

Liu

Thomas

Googe

. Immunohistochemical expression of PD-L1 is increased in lesional epidermal keratinocytes in Stevens-Johnson syndrome/toxic epidermal necrolysis. Am J Dermatopathol. 2021;43(4):318-320. doi:10.1097/DAD.0000000000001816

Schneider

Naidoo

Santomasso

, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update [published correction appears in J Clin Oncol. 2022 Jan 20;40(3):315. doi:10.1200/JCO.21.02786]. J Clin Oncol. 2021;39(36):4073-4126. doi:10.1200/JCO.21.01440

Sun

Xiang

Liu

. Severe cutaneous adverse reactions associated with immune checkpoint inhibitors therapy and anti-VEGF combination therapy: a real-world study of the FDA adverse event reporting system. Expert Opin Drug Saf. 2024;23(6):777-784. doi:10.1080/14740338.2023.2251381

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.03 MB

0.12 MB

0.02 MB

2.52 MB